LRMR
Larimar Therapeutics, Inc.
$4.28
+0.15
(+3.63%)
Mkt Cap
366.27M
Volume
3,435,877
52W Range
2.715-6.42
Sector
Healthcare
Beta
0.84
EPS (TTM)
-2.10
P/E Ratio
-1.68
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (165.67M) | (80.60M) | (36.95M) | (35.35M) | (50.64M) | (42.33M) | (23.13M) | (61.37M) | (52.03M) | (57.88M) | (74.29M) | (36.57M) |
| EPS | -2.27 | -1.32 | -0.84 | -1.33 | -2.93 | -3.56 | -2.51 | -22.85 | -22.76 | -25.44 | -33.32 | -15.14 |
| Free Cash Flow | (113.29M) | (71.28M) | (33.62M) | (27.67M) | (42.44M) | (42.26M) | (22.78M) | (51.59M) | (43.84M) | (52.63M) | (60.15M) | (28.30M) |
| FCF / Share | -1.55 | -1.16 | -0.77 | -1.07 | -2.47 | -3.56 | -2.47 | -19.21 | -19.18 | -23.14 | -26.98 | -11.71 |
| Operating CF | (113.20M) | (70.76M) | (33.46M) | (27.57M) | (42.10M) | (42.20M) | (22.70M) | (51.49M) | (43.78M) | (51.98M) | (59.55M) | (28.24M) |
| Total Assets | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M | 104.69M | 5.20M | 121.76M | 105.51M | 131.62M | 189.11M | 117.52M |
| Total Debt | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M | 6.52M | 97,000 | 20.64M | 20.00M | 3.59M | 6.39M | 7.56M |
| Cash & Equiv | 85.41M | 33.22M | 26.75M | 26.82M | 70.10M | 68.15M | 1.01M | 49.33M | 40.78M | 32.35M | 35.59M | 58.10M |
| Book Value | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M | 89.69M | (694,000) | 93.27M | 78.22M | 121.73M | 169.11M | 104.44M |
| Return on Equity | -2.12 | -0.47 | -0.45 | -0.32 | -0.79 | -0.47 | N/A | -0.66 | -0.67 | -0.48 | -0.44 | -0.35 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (29.61M) | (62.50M) | (47.71M) | (26.18M) | (29.28M) | (28.82M) | (15.50M) | (21.63M) | (14.65M) | (12.99M) | (9.06M) | (8.37M) |
| EPS | -0.35 | -0.73 | -0.61 | -0.41 | -0.46 | -0.45 | -0.24 | -0.34 | -0.27 | -0.30 | -0.21 | -0.19 |
| Free Cash Flow | (44.61M) | (38.53M) | (28.78M) | (19.40M) | (26.59M) | (21.99M) | (24.61M) | (14.26M) | (10.41M) | (9.51M) | (9.20M) | (7.37M) |
| FCF / Share | -0.52 | -0.45 | -0.37 | -0.30 | -0.42 | -0.34 | -0.39 | -0.22 | -0.19 | -0.22 | -0.21 | -0.17 |
| Operating CF | (44.61M) | (38.53M) | (28.75M) | (19.38M) | (26.54M) | (21.82M) | (24.55M) | (13.99M) | (10.41M) | (9.34M) | (9.20M) | (7.37M) |
| Total Assets | 208.51M | 145.84M | 187.35M | 149.99M | 170.18M | 200.22M | 219.02M | 237.16M | 248.21M | 95.94M | 103.95M | 111.72M |
| Total Debt | 3.78M | 4.07M | 4.35M | 4.61M | 4.87M | 5.12M | 5.36M | 5.59M | 5.34M | 5.55M | 5.39M | 5.08M |
| Cash & Equiv | 177.91M | 85.41M | 90.14M | 20.59M | 21.13M | 33.22M | 35.07M | 32.31M | 110.12M | 26.75M | 38.72M | 94.32M |
| Book Value | 158.03M | 78.08M | 139.04M | 119.85M | 144.27M | 171.81M | 198.40M | 211.40M | 230.84M | 81.72M | 92.71M | 99.93M |
| Return on Equity | -0.19 | -0.80 | -0.34 | -0.22 | -0.20 | -0.17 | -0.08 | -0.10 | -0.06 | -0.16 | -0.10 | -0.08 |
LRMR News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results